Maplight Therapeutics
Clinical trials sponsored by Maplight Therapeutics, explained in plain language.
-
New pill tested to calm severe schizophrenia episodes
Disease control Recruiting nowThis study is testing an investigational oral medication called ML-007C-MA for adults hospitalized due to a sudden, severe worsening of schizophrenia symptoms (acute psychosis). The goal is to see if it is better than a placebo at reducing overall schizophrenia symptoms, as measu…
Phase: PHASE2 • Sponsor: MapLight Therapeutics • Aim: Disease control
Last updated Mar 12, 2026 13:52 UTC
-
New drug aims to quiet the distressing voices and false beliefs of Alzheimer's psychosis
Symptom relief Recruiting nowThis study is testing whether an investigational drug called ML-007C-MA can safely reduce hallucinations and delusions in people with Alzheimer's disease. It will involve about 300 participants, aged 55 to 90, who experience these specific symptoms. The drug will be compared agai…
Phase: PHASE2 • Sponsor: MapLight Therapeutics • Aim: Symptom relief
Last updated Apr 01, 2026 14:41 UTC